Dirk Waldschmidt

3.7k total citations
68 papers, 924 citations indexed

About

Dirk Waldschmidt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Dirk Waldschmidt has authored 68 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Dirk Waldschmidt's work include Pancreatic and Hepatic Oncology Research (33 papers), Cancer Genomics and Diagnostics (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers). Dirk Waldschmidt is often cited by papers focused on Pancreatic and Hepatic Oncology Research (33 papers), Cancer Genomics and Diagnostics (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers). Dirk Waldschmidt collaborates with scholars based in Germany, United States and Spain. Dirk Waldschmidt's co-authors include Alexander Quaas, Christiane J. Bruns, Teresa Macarulla, Oliver A. Cornely, Michael von Bergwelt‐Baildon, Anthony B. El-Khoueiry, Robin Kate Kelley, Fabian Kütting, Stefan Boeck and Thomas Zander and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Hepatology.

In The Last Decade

Dirk Waldschmidt

62 papers receiving 912 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Waldschmidt Germany	17	607	263	210	186	175	68	924
Roberta Cerutti Italy	18	343 0.6×	154 0.6×	171 0.8×	193 1.0×	283 1.6×	58	988
Yabing Cao China	15	350 0.6×	135 0.5×	131 0.6×	132 0.7×	189 1.1×	52	811
Vera Schellerer Germany	20	550 0.9×	270 1.0×	294 1.4×	160 0.9×	95 0.5×	60	1.1k
Yufan Cheng China	16	385 0.6×	210 0.8×	326 1.6×	169 0.9×	120 0.7×	51	949
Hideaki Yano Japan	17	332 0.5×	169 0.6×	496 2.4×	68 0.4×	210 1.2×	66	1.0k
Chantal Dreyer France	19	387 0.6×	201 0.8×	148 0.7×	131 0.7×	245 1.4×	57	966
Kohei Shigeta Japan	15	590 1.0×	210 0.8×	260 1.2×	157 0.8×	117 0.7×	75	945
Feng Ye China	18	333 0.5×	223 0.8×	92 0.4×	431 2.3×	131 0.7×	57	1.1k
Joris I. Erdmann Netherlands	17	670 1.1×	456 1.7×	590 2.8×	153 0.8×	193 1.1×	85	1.1k

Countries citing papers authored by Dirk Waldschmidt

Since Specialization

Citations

This map shows the geographic impact of Dirk Waldschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Waldschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Waldschmidt more than expected).

Fields of papers citing papers by Dirk Waldschmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Waldschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Waldschmidt. The network helps show where Dirk Waldschmidt may publish in the future.

Co-authorship network of co-authors of Dirk Waldschmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Waldschmidt. A scholar is included among the top collaborators of Dirk Waldschmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Waldschmidt. Dirk Waldschmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Man, Sofia, et al.. (2025). Resistance training in cachectic pancreatic and lung cancer patients: randomised controlled trial. BMJ Supportive & Palliative Care. 16(1). 112–121.

Spielmann, S., Alexander Damanakis, Yue Zhao, et al.. (2024). Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Translational Oncology. 47. 102044–102044. 11 indexed citations

Zhang, Danmei, C. Benedikt Westphalen, Michael Quante, et al.. (2024). Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial. European Journal of Cancer. 201. 113926–113926. 5 indexed citations

Heinemann, Volker, Laura Fischer, Frank Gieseler, et al.. (2023). SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group. Annals of Oncology. 34. S164–S164. 1 indexed citations

Siveke, Jens T., Marianne Sinn, Stefan Boeck, et al.. (2023). Abstract CT195: Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nab-paclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Cancer Research. 83(8_Supplement). CT195–CT195. 1 indexed citations

Gebauer, Florian, Alexander Damanakis, Felix Popp, et al.. (2021). Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 21(1). 1239–1239. 19 indexed citations

Vogel, Arndt, Anna Saborowski, Thomas J. Ettrich, et al.. (2021). LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC). Annals of Oncology. 32. S1312–S1312. 8 indexed citations

Perkhofer, Lukas, Jana K. Striefler, Marianne Sinn, et al.. (2021). LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Annals of Oncology. 32. S1282–S1282. 11 indexed citations

Ceccon, Garry, Anna Brunn, Martina Deckert, et al.. (2020). Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Case Reports in Oncology. 13(1). 35–42. 7 indexed citations

10.

Galle, Peter R., Max W. Sung, William Proctor Harris, et al.. (2020). 990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Annals of Oncology. 31. S691–S692. 9 indexed citations

11.

Westphalen, C. Benedikt, Benjamin Garlipp, Martin Fuchs, et al.. (2020). Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study. BMC Cancer. 20(1). 155–155. 4 indexed citations

12.

Thelen, Martin, Philipp Gödel, Axel Lechner, et al.. (2020). Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunology Immunotherapy. 70(4). 893–907. 105 indexed citations

13.

Quaas, Alexander, Carina Heydt, Dirk Waldschmidt, et al.. (2019). Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. BMC Gastroenterology. 19(1). 21–21. 7 indexed citations

14.

Tempero, Margaret A., Do‐Youn Oh, Teresa Macarulla, et al.. (2019). Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Annals of Oncology. 30. iv126–iv126. 16 indexed citations

15.

Damanakis, Alexander, Luisa M. Ostertag, Dirk Waldschmidt, et al.. (2019). Proposal for a definition of "Oligometastatic disease in pancreatic cancer". BMC Cancer. 19(1). 1261–1261. 33 indexed citations

16.

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of Oncology. 29. viii720–viii720. 33 indexed citations

17.

Demir, Münevver, Fabian Kütting, Andrea Bowe, et al.. (2015). Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection. 43(2). 153–162. 3 indexed citations

18.

Kütting, Fabian, et al.. (2015). Neuroendocrine Carcinoma of the Gallbladder Masquerading as a Klatskin Tumor in a 74-Year-Old Male. Journal of Gastrointestinal Cancer. 47(1). 118–122. 4 indexed citations

19.

Vehreschild, Maria J. G. T., Lena M. Biehl, Daniela Tacke, et al.. (2014). Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. Biology of Blood and Marrow Transplantation. 20(6). 823–828. 43 indexed citations

20.

Boeck, Stefan, Ursula Vehling‐Kaiser, Dirk Waldschmidt, et al.. (2009). Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anti-Cancer Drugs. 21(1). 94–100. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact